Tolmar, Inc., founded in 2007 and headquartered in Fort Collins, Colorado, is a specialty pharmaceutical company focused on developing, manufacturing, and commercializing long-acting injectable treatments across urology, oncology, and endocrinology. The company operates a 300,000 ft² state-of-the-art facility housing chemistry and microbiology labs, multishift production, and cGMP-compliant manufacturing.

Tolmar is best known for ELIGARD® (leuprolide acetate for injectable suspension), a leading therapy for advanced prostate cancer, and has expanded its portfolio through strategic acquisitions such as JATENZO and Clarus Therapeutics. With 1,000–5,000 employees and growing industry recognition, Tolmar emphasizes sustainability, patient-centered innovation, and partnership with healthcare providers.

Key Features & Benefits: